Table 4A.

Mean and standard deviations for various parameters per interventions by Tukey's HSD test.

Parameters	Time	Interventions			Post-hoc test by Tukey HSD
		Placebo	USC	CGM	F -values	P -values
Tau protein (pg/ml)	Baseline	26.92 ± 4.37a	26.10 ± 3.83a	26.14 ± 4.27a	12.27	0.886
	End of study	31.72 ± 3.72a,b	25.86 ± 3.34b,a	24.66 ± 4.01b,b		0.001
BDNF (pg/ml)	Baseline	57.54 ± 9.25a	57.92 ± 7.55a	62.00 ± 8.53a	5.933	0.399
	End of study	55.09 ± 7.58a,a	60.00 ± 7.56b,a	66.28 ± 9.04b,b		0.005
Aβ-42 (pg/ml)	Baseline	31.70 ± 2.49a	33.31 ± 2.99a	32.06 ± 2.95a	25.37	0.898
	End of study	35.24 ± 2.72a,b	32.46 ± 2.84a,a	31.28 ± 4.48b,b		0.001
IL-6 (μg/L)	Baseline	3.40 ± 1.38a	3.64 ± 1.74a	3.70 ± 0.93a	3.332	0.848
	End of study	3.80 ± 1.72a,b	2.92 ± 1.66a,a	2.37 ± 0.50b,b		0.037
TNF-α (μg/L)	Baseline	2.04 ± 0.23a	2.09 ± 0.44a	2.12 ± 0.28a	96.01	0.804
	End of study	2.46 ± 0.36a,b	1.78 ± 0.15b,a	0.93 ± 0.29c,b		0.001
MMSE	Baseline	16.09 ± 1.86a	15.69 ± 1.70a	16.07 ± 1.81a	39.28	1.000
	End of study	13.81 ± 1.72a,b	16.15 ± 1.14b,a	19.21 ± 1.67c,b		0.001
GLFS	Baseline	17.36 ± 1.85a	16.53 ± 1.56a	16.92 ± 2.01a	40.41	0.826
	End of study	18.54 ± 1.75a,a	15.46 ± 1.45b,a	12.71 ± 1.63c,b		0.001

Significant interactions among placebo, USC and CGM groups were analyzed by Turkey HSD. The values are expressed as mean ± SD. F-value and P-value were also provided. Means not sharing subscripts differ significantly at P < 0.05 as indicated by Tukey HSD. The first superscript in “End of Study” denotes significance level of intergroup comparison by Tukey HSD post hoc analysis and second super script in “End of Study” denotes significance level of pairwise comparison.